PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
31.77%
Cash & equivalents growing 31.77% while AGEN's declined -12.50%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
31.77%
Below half of AGEN's -12.50%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.02%
Below half of AGEN's -9.30%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.80%
Below half AGEN's 44.53%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.28%
Below half of AGEN's 27.46%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.41%
≥ 1.5x AGEN's 4.91%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
2.77%
Less than half of AGEN's -17.17%. David Dodd sees a more disciplined AP approach or lower volume.
1023.68%
Less than half of AGEN's -29.53%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.85%
Below half of AGEN's -57.16%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
1.86%
Less than half of AGEN's -11.58%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.95%
Less than half of AGEN's 12.21%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of AGEN's 3.70%. David Dodd sees far fewer liability expansions relative to competitor.
28.57%
Above 1.5x AGEN's 3.65%. Michael Burry suspects heavy new equity expansion or dilution.
-2.84%
Similar yoy to AGEN's -2.63%. Walter Schloss sees parallel earnings retention vs. competitor.
100.00%
Similar yoy to AGEN's 124.82%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
34.98%
Below half AGEN's -2.61%. Michael Burry sees potential underperformance in building shareholder capital.
31.41%
≥ 1.5x AGEN's 4.91%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-15.85%
Less than half of AGEN's 51.63%. David Dodd sees less overall debt expansion vs. competitor.
-32.66%
Less than half of AGEN's 42.96%. David Dodd sees better deleveraging or stronger cash buildup than competitor.